SOLANA BEACH, Calif. — September 29, 2025 — Leads & Copy — Artelo Biosciences, Inc. (Nasdaq: ARTL) has announced the commencement of an underwritten public offering of its common stock and/or pre-funded warrants. The clinical-stage pharmaceutical company, which focuses on modulating lipid-signaling pathways to develop treatments for cancer, pain, dermatologic, or neurological conditions, will offer all shares of common stock and/or pre-funded warrants. The offering is subject to market conditions, with no assurance as to its completion, size, or terms.
R.F. Lafferty & Co., Inc. is the sole book-running manager for the offering.
The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-273153), filed with the SEC and declared effective on July 14, 2023. The offering is made via a prospectus supplement and accompanying prospectus. Details will be available on the SEC’s website and from R. F. Lafferty & Co., Inc.
This announcement is not an offer to sell or a solicitation to buy securities, nor will there be any sale in any jurisdiction where such actions would be unlawful.
Artelo Biosciences develops and commercializes proprietary therapeutics modulating lipid-signaling pathways, addressing unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. The company applies scientific, regulatory, commercial, and treasury management practices to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
Source: Artelo Biosciences, Inc.
